Onclive Camrelizumab Plus
Onclive Camrelizumab Plus entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.
Timeline
Tue, 04 Aug 2026 15:51:00 GMTCamrelizumab Plus Nab-Paclitaxel Yields Efficacy in Previously Treated Advanced Urothelial Carcinoma - OncLive
Mon, 03 Aug 2026 19:45:56 GMTTislelizumab Plus Gemcitabine Shows Efficacy in Cisplatin-Ineligible Urothelial Carcinoma - OncLive
Related explainers
Connected entities
Paclitaxel Yields Efficacy2 live mentionsPreviously Treated Advanced2 live mentionsCisplatin2 live mentionsIneligible Urothelial Carcinoma2 live mentionsCamrelizumab Plus Nab1 live mentionsUrothelial Carcinoma1 live mentionsNab1 live mentionsUrothelial Carcinoma OncLive1 live mentionsOncLive1 live mentionsTislelizumab Plus Gemcitabine1 live mentions
FAQ
What does this page track?
Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Onclive Camrelizumab Plus.
Why might this page be noindex?
Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.
Where should readers verify facts?
Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.
Source diversity
1 distinct publisher/source names are currently connected to this entity page.